SOMNF (SomnoMed) Moat Score: 4/10 (As of Jul. 01, 2026)


SOMNF SomnoMed Ltd SOMNF
49 GF Score
Price $0.45
GF Value $0.33
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is SomnoMed Moat Score?

SomnoMed SOMNF 49 Moat Score is 4 as of Jul. 01, 2026. GuruFocus rates SOMNF with a GF Score™ of 49/100 and a GF Value™ of $0.33 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 846 Medical Devices & Instruments companies, SomnoMed ranks better than 83.33% on this metric.

SomnoMed has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

SomnoMed has Narrow Moat: SomnoMed Ltd has a modest moat due to its specialized medical devices and some customer loyalty. However, the lack of significant regulatory barriers and moderate brand strength limit its competitive advantages.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes SomnoMed might have Narrow Moat - Discernible but modest moat.

SomnoMed  (OTCPK:SOMNF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

SomnoMed Moat Score Related Terms

SOMNF vs ABT, SYK, MDT: Moat Score Comparison

For the Medical Devices subindustry, SomnoMed's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SomnoMed Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, SomnoMed's Moat Score distribution charts can be found below:

* The bar in red indicates where SomnoMed's Moat Score falls into.


SOMNF
49GF Score
SomnoMed Ltd SOMNF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
SomnoMed (SOMNF) has a Moat Score of 4 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, SomnoMed ranks #141 out of 846 companies in the Medical Devices & Instruments industry, placing it in the top 16.7%.
Is SomnoMed's Moat Score too high?
SomnoMed's current Moat Score is 4. Based on the distribution chart, SomnoMed ranks #141 out of 846 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, SomnoMed has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SomnoMed's Moat Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, SomnoMed ranks #141 out of 846 companies for Moat Score. This places SomnoMed in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. SomnoMed's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SomnoMed stock overvalued right now?
Based on GuruFocus' analysis, SomnoMed (SOMNF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.33, compared to a current price of $0.45 — trading 35.7% above its estimated fair value. The current Moat Score is 4. SomnoMed's overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For SomnoMed (SOMNF), the current Moat Score is 4 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SomnoMed (SOMNF) Overvalued in 2026?

Based on GuruFocus' analysis, SomnoMed stock appears to be overvalued. The current stock price of $0.45 is trading 35.7% above its estimated GF Value™ of $0.33. GuruFocus considers SomnoMed to be Significantly Overvalued.

Key valuation signals for SOMNF:

  • Moat Score: 4
  • GF Value™: $0.33 vs. price of $0.45 (35.7% above fair value)
  • GF Score™: 49/100 with 3 warning signs

No single metric tells the full story. See the SOMNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SomnoMed Business Description

Other Exchanges RJV:GermanySOM:Australia
Address 20 Clarke Street, Level 3, Crows Nest, Sydney, NSW, AUS, 2065
SomnoMed Ltd provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. It is engaged in commercializing SomnoDent Mandibular Advancement Splint (MAS) and other oral devices for sleep-related disorders in Australia and overseas. The other products in the company's portfolio include SomMorning Repositioner; SomnoBrux splint, a custom-fit, acrylic splint (dental guard) for upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs cleaning tablets that have been developed to clean oral appliances. Geographically, the company generates maximum revenue from Europe, followed by North America and the Asia Pacific region.
49GF Score

Get the complete analysis for SOMNF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.45
Price
$0.33
GF Value